GREENVILLE, South Carolina, June 14, 2022 /PRNewswire/ — First medical laboratory services (PMLS), a national laboratory for advanced medical diagnostics, adds AditxtScore™ to its menu of testing services. Providing greater clarity regarding a patient’s individual immune profile, AditxtScore™ allows patients to know their level of protection that an immune response to the virus or vaccination has provided them. Now that a large part of the population has been vaccinated or has experienced symptomatic or asymptomatic infection with SARS-CoV-2, AditxtScoreä provides information on the immune status during the current phase of the pandemic.
“As new variants emerge, we want to equip doctors with the most advanced tests that allow a complete view of their patient’s health status,” said Kevin Murdock, CEO of Premier Medical Laboratory Services. “With AditxtScoreä, individuals can make more informed decisions about whether vaccinations, boosters or other risk mitigation strategies are the right course of action for them.”
PMLS, a CAP-accredited lab that has processed more than 3.5 million COVID-19 tests and hosts one of the nation’s largest next-generation sequencing variant tracing platforms, is committed to providing the most progress in the fight against COVID-19 over the past two years. years. Although the virus continues to spread and the implications of new variants are unknown, it is essential to monitor transmission rates, severity of infection and immune trends. AditxtScore® can be used routinely to identify changes in immune response over time and greatly contribute to the ongoing understanding of responses to SARS-CoV-2. The test can also provide needed information to individuals and, in some cases, can help minimize vaccine hesitancy for those who are not protected by antibodies.
AditxtScoreä results provide answers to the following questions for an individual:
- Does the individual have antibodies present?
- Are the individual’s antibodies present as a result of vaccination or an immune response to infection with the virus?
- Is the individual’s immune response likely to provide protection against future infection?
- What are possible ways to minimize the risk of future infection (eg, increase or limit exposure)?
Along with a blood draw, AditxtScore™ provides an assessment of several types of antibodies against several SARS-CoV-2 antigens. AditxtScore™ also measures levels of neutralizing antibodies, which block viral entry into human cells. A proprietary algorithm is used to evaluate and translate clinical data into meaningful information for individuals. Interpretative information about the results and possible ways to minimize risk is then provided to the patient. Developed at the CLIA-certified and CAP-accredited AditxtScore™ center, led by laboratory scientists trained at prestigious institutions such as Mayo Clinic and Stanford Universitythe test is complete and accurate.
In addition to the additional clarity an individual can gain regarding their own immunity profile, employers can use AditxtScoreä to save time and money with their COVID-19 testing efforts by managing testing frequency. The test can also help minimize lost time and wages for employees with less frequent quarantines. Finally, it can ensure employee safety by identifying employees most at risk of infection.
AditxtScore™ is offered by Premier Medical Laboratory Services as an authorized distribution partner. Additional terms, conditions and restrictions may apply. Please click on the following link for more information https://premedinc.com/aditxtscore-immune/
Premier Medical Laboratory Services (PMLS), headquartered in Greenville, South Carolina, is the Official Health and Wellness Partner of Greenville Triumph and an Advanced Molecular Diagnostics Laboratory fully certified by top laboratory accrediting organizations including CLIA and COLA. PMLS is proud to offer some of the fastest test result turnaround times in the industry and patient friendly billing. Their extensive menu of highly advanced tests and screenings includes genomic risk assessment tests for various cancers, heart disease and diabetes, as well as panels on women’s health, toxicology, allergy testing, pharmacogenomics, routine blood chemistry and non-invasive prenatal testing (NIPT). With a sincere mission to improve patient care, their in-house research and development team of PhD scientists and forward-thinking laboratory staff are constantly innovating to provide the most advanced medical diagnostics available. For more information on PMLS, please visit www.premedinc.com or call 866.312.4707.
Aditxt (NASDAQ: ADTX) is a biotechnology innovation company that develops and commercializes technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to transplant organ rejection, autoimmune diseases and allergies.
SOURCE Premier Medical Laboratory Services